Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.40 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.38 |
| ▸ | NQO2 | P16083 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.37 |
| ▸ | RELA | Q04206 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12810257 | 0.86 | AAK1 (0.52) | CASRSMN1; SMN2MAPTTP53DYRK1A | |
| SCHEMBL12591857 | 0.85 | RAB9A (0.58) | CASRSMN1; SMN2MAPTTP53DYRK1A | |
| SCHEMBL23328427 | 0.83 | CASR (0.47) | CASRSMN1; SMN2MAPTTP53DYRK1A | |
| SCHEMBL12810070 | 0.82 | AAK1 (0.46) | CASRSMN1; SMN2MAPTTP53RAB9A | |
| SCHEMBL889391 | 0.81 | RAB9A (0.49) | CASRSMN1; SMN2MAPTTP53RAB9A | |
| SCHEMBL15481036 | 0.80 | SMN1; SMN2 (0.56) | SMN1; SMN2RAB9AAAK1LOXL2NPC1 | |
| SCHEMBL15481035 | 0.80 | PPARA (0.51) | CASRDYRK1ARAB9AAAK1LOXL2 | |
| SCHEMBL4284575 | 0.80 | DYRK1A (0.50) | CASRSMN1; SMN2MAPTDYRK1ARAB9A | |
| SCHEMBL4973853 | 0.80 | MAPT (0.53) | CASRSMN1; SMN2MAPTTP53RAB9A | |
| SCHEMBL24690847 | 0.80 | AAK1 (0.40) | CASRSMN1; SMN2TP53RAB9AAAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373930-A1 | AMINOIMIDAZOLE FPR2 AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2023-11-23 | — | — | US | disclosed |
| US-11701333-B2 | Antibacterial compounds | Kent Innovation & Enterprise (GB) | 2023-07-18 | — | — | US | disclosed |
| US-11701333-B2 | Antibacterial compounds | Kent Innovation & Enterprise (GB) | 2023-07-18 | — | — | US | disclosed |
| US-20230159512-A1 | COMPOUNDS AS GLP-1R AGONISTS | TERNS PHARMACEUTICALS, INC. | 2023-05-25 | — | — | US | disclosed |
| WO-2023023310-A1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. (US) | 2023-02-23 | — | — | WO | disclosed |
| US-20210128501-A1 | ANTIBACTERIAL COMPOUNDS | KENT INNOVATION & ENTERPRISE, UNIVERSITY OF KENT (GB) | 2021-05-06 | — | — | US | disclosed |
| US-20190112312-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2019-04-18 | — | — | US | disclosed |
| US-10189830-B2 | Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders | BIOELECTRON TECHNOLOGY CORPORATION (US) | 2019-01-29 | — | — | US | disclosed |
| US-20170015671-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC | 2017-01-19 | — | — | US | disclosed |
| US-9533991-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2017-01-03 | — | — | US | disclosed |
| US-20110142798-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-06-16 | — | — | US | disclosed |
| US-20110070197-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-03-24 | — | — | US | disclosed |
| US-20110070196-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-03-24 | — | — | US | disclosed |
| US-20110064695-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-03-17 | — | — | US | disclosed |
| US-20110064698-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-03-17 | — | — | US | disclosed |
| US-20110008288-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-01-13 | — | — | US | disclosed |
| WO-2010148006-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2010-12-23 | — | — | WO | disclosed |
| US-20100316607-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2010-12-16 | — | — | US | disclosed |
| US-20100266543-A1 | LINKED DIBENZIMIDAZOLE ANTIVIRALS | ENANTA PHARMACEUTICALS, INC. | 2010-10-21 | — | — | US | disclosed |
| US-20100260715-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11701333-B2 | Antibacterial compounds | ARF1, ARL1, TLR1 | CASR 4392/4885SMN1; SMN2 3087/4885MAPT 2612/4885 |
| US-20100260715-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | CASR 4563/4885SMN1; SMN2 4162/4885MAPT 4133/4885 |
| US-20100316607-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | CASR 4563/4885SMN1; SMN2 4162/4885MAPT 4133/4885 |
| US-20230159512-A1 | COMPOUNDS AS GLP-1R AGONISTS | GLP1R, GIPR, GCGR | CASR 218/4885SMN1; SMN2 2580/4885MAPT 3437/4885 |
| US-20170015671-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LYN, SYK | CASR 4746/4885SMN1; SMN2 4440/4885MAPT 4267/4885 |
| US-20110142798-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | CASR 4563/4885SMN1; SMN2 4162/4885MAPT 4133/4885 |
| US-20110008288-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | CASR 4563/4885SMN1; SMN2 4162/4885MAPT 4133/4885 |
| US-20100266543-A1 | LINKED DIBENZIMIDAZOLE ANTIVIRALS | EIF2AK2, ZC3HAV1, NSUN2 | CASR 4854/4885SMN1; SMN2 3504/4885MAPT 3942/4885 |
| US-20110070196-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, EIF2AK2, SLC10A1 | CASR 4527/4885SMN1; SMN2 4269/4885MAPT 4286/4885 |
| US-20190112312-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LYN, SYK | CASR 4746/4885SMN1; SMN2 4440/4885MAPT 4267/4885 |
| US-20110064698-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, EIF2AK2, SLC10A1 | CASR 4527/4885SMN1; SMN2 4269/4885MAPT 4286/4885 |
| US-20110064695-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, EIF2AK2, SLC10A1 | CASR 4527/4885SMN1; SMN2 4269/4885MAPT 4286/4885 |
| US-20230373930-A1 | AMINOIMIDAZOLE FPR2 AGONISTS | FPR2, FPR1, FPR3 | CASR 1563/4885SMN1; SMN2 4462/4885MAPT 4406/4885 |
| US-10189830-B2 | Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders | NQO1, COQ8A, NDUFAB1 | CASR 4810/4885SMN1; SMN2 303/4885MAPT 664/4885 |
| US-20110070197-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, EIF2AK2, SLC10A1 | CASR 4527/4885SMN1; SMN2 4269/4885MAPT 4286/4885 |
| US-20210128501-A1 | ANTIBACTERIAL COMPOUNDS | ARF1, ARL1, TLR1 | CASR 4392/4885SMN1; SMN2 3087/4885MAPT 2612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.